Physician profile
Michael E Cash
NPI 1255511887
$2,957.17
in general payments reported to CMS, 2019-2025
24 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $248 · 2021: $318 · 2022: $489 · 2023: $618 · 2024: $798 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $539.75 | 2020-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.78 | 2023-2025 | Lifevest |
| Amgen INC. | $352.71 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $315.60 | 2021-2025 | |
| Pfizer INC. | $273.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $263.29 | 2020-2024 | Farxiga, Andexxa |
| Kestra Medical Technology Services, INC. | $158.43 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $140.14 | 2021-2025 | Camzyos, Eliquis |
| Ge Healthcare | $85.79 | 2020 | |
| Siemens Medical Solutions USA, INC. | $66.26 | 2024 | Acuson Sequoia Diagnostic Ultrasound System, Acuson Freestyle Diagnostic Ultrasound System, Acuson Origin Diagnostic Ultrasound System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.73 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $48.65 | 2024 | Ozempic |
| Lantheus Medical Imaging, INC. | $45.85 | 2022-2023 | Definity |
| Actelion Pharmaceuticals US, INC. | $45.05 | 2022 | |
| Medtronic, INC. | $30.35 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.20 | 2024 | Cardiomems |
| Abiomed | $22.84 | 2023 | Impella |
| Alnylam Pharmaceuticals INC. | $22.25 | 2024 | Onpattro |
| Livanova USA, INC. | $22.05 | 2022 | |
| Biosense Webster, INC. | $20.09 | 2022 | |
| Endotronix, INC. | $19.84 | 2021 | |
| Merck Sharp & Dohme LLC | $19.14 | 2025 | Verquvo |
| Biotronik INC. | $18.49 | 2022 | |
| Esperion Therapeutics, INC. | $13.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.